Diabetes trends in Europe

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue SUPPL. 3, 2002, Pages

  Passa, Philippe ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Epidemic expansion; Health care costs; Macrovascular complications; Microvascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG MARKETING; EPIDEMIC; FEMALE; FINLAND; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL CARE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SPAIN; UNITED KINGDOM;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EUROPE; GEOGRAPHY; HUMANS; INCIDENCE; PREVALENCE;

EID: 0036711087     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.276     Document Type: Article

References (27)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl. 5): S1-S85.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
3. Alberti KGMM, Zimmet P, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
4. Zimmet P, Turner C, McCarty D, Rowley M, MacKay I. Crucial points at diagnosis of type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22 (Suppl. 2): B59-B64.
5. Levy-Marchal C. Evolution of the incidence of IDDM in childhood in France. Rev Epidemiol Sante Publique 1998; 46: 157-163.
6. Tuomilehto J, Karvonen M, Pitkäniemi J, et al. Record-high incidence of Type I (insulin-dependent) diabetes mellitus in Finnish children. The Finnish Childhood Type I Diabetes Registry Group. Diabetologia 1999; 42: 655-660.
7. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000; 355: 873-876.
8. Passa P. How many diabetic patients are there in France? Diabetes Metab 1999; 25: 366-367.
9. Ricordeau P, Weill A, Vallier N, Bourrel R, Fender P, Allemand H. Epidemiology of diabetes in metropolitan France. Diabetes Metab 2000; 26 (Suppl. 6): 11-24.
10. Vilbergsson S, Sigurdsson G, Sigvaldason H, Hreidarsson AB, Sigfusson N. Prevalence and incidence of NIDDM in Iceland: evidence for stable incidence among males and females 1967-1991. The Reykjavik Study. Diabet Med 1997; 14: 491-498.
11. Gatling W, Budd S, Walters D, Mullee MA, Goddard JR, Hill RD. Evidence of an increasing prevalence of diagnosed diabetes mellitus in the Poole area from 1983 to 1996. Diabet Med 1998; 15: 1015-1021.
12. Berger B, Stenstrom G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care 1999; 22: 773-778.
13. Detournay B, Vauzelle-Kervroedan F, Charles MA, et al. Epidemiology, management and costs of type 2 diabetes in France in 1998. Diabetes Metab 1999; 25: 356-365.
14. CODE-2: revealing the costs of type 2 diabetes in Europe. EASD Satellite Symposium Report, Brussels, 27 September 1999.
15. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
16. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 year's therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
17. Gourdy P, Ruidavets JB, Ferrieres J, et al. Hyperglycémie à jeun et facteurs de risque cardiovasculaire. Etude MONICA 1995-1997. Diabetes Metab 1999; 25 (Suppl. 1): A07.
18. Laurent S, Lasfargues G, Vol S, Combe H, Tichet J, LeCompte P. Prévalence du diabète de type 2 méconnu et facteurs de risque cardiovasculaires associés: impact des nouveaux critères. Diabetes Metab 1999; 25 (Suppl. 1): A013.
19. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Diabetologia 1999; 42: 647-654.
20. Garancini MP, Calori G, Ruotolo G, et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 1995; 38: 306-313.
21. Hiltunen L, Luukinen H, Koski K, Kivelä SL. Prevalence of diabetes mellitus in an elderly Finnish population. Diabet Med 1994; 11: 241-249.
22. Halimi S, Zmirou D, Benhamou PY, et al. Huge progression of diabetes prevalence and incidence among dialysed patients in mainland France and overseas French territories. A second national study six years apart (UREMIDIAB 2 Study). Diabetes Metab 1999; 25: 507-512.
23. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-713.
25. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
26. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO HOPE substudy. Lancet 2000; 355: 253-259.
27. Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293-1301.